Alkaloids as Natural NRF2 Inhibitors: Chemoprevention and Cytotoxic Action in Cancer.

NRF2 inhibitors alkaloids anticancer therapy cancer chemoprevention plant bioactive compound

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
07 Jun 2023
Historique:
received: 05 05 2023
revised: 28 05 2023
accepted: 04 06 2023
medline: 28 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Being a controller of cytoprotective actions, inflammation, and mitochondrial function through participating in the regulation of multiple genes in response to stress-inducing endogenous or exogenous stressors, the transcription factor Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) is considered the main cellular defense mechanism to maintain redox balance at cellular and tissue level. While a transient activation of NRF2 protects normal cells under oxidative stress, the hyperactivation of NRF2 in cancer cells may help them to survive and to adapt under oxidative stress. This can be detrimental and related to cancer progression and chemotherapy resistance. Therefore, inhibition of NRF2 activity may be an effective approach for sensitizing cancer cells to anticancer therapy. In this review, we examine alkaloids as NRF2 inhibitors from natural origin, their effects on cancer therapy, and/or as sensitizers of cancer cells to anticancer chemotherapeutics, and their potential clinical applications. Alkaloids, as inhibitor of the NRF2/KEAP1 signaling pathway, can have direct (berberine, evodiamine, and diterpenic aconitine types of alkaloids) or indirect (trigonelline) therapeutic/preventive effects. The network linking alkaloid action with oxidative stress and NRF2 modulation may result in an increased NRF2 synthesis, nuclear translocation, as well in a downstream impact on the synthesis of endogenous antioxidants, effects strongly presumed to be the mechanism of action of alkaloids in inducing cancer cell death or promoting sensitivity of cancer cells to chemotherapeutic agents. In this regard, the identification of additional alkaloids targeting the NRF2 pathway is desirable and the information arising from clinical trials will reveal the potential of these compounds as a promising target for anticancer therapy.

Identifiants

pubmed: 37375797
pii: ph16060850
doi: 10.3390/ph16060850
pmc: PMC10300961
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Drug Des Devel Ther. 2018 Apr 03;12:721-733
pubmed: 29662304
Mol Cell Biol. 2003 Nov;23(22):8137-51
pubmed: 14585973
J Biol Chem. 2012 Mar 23;287(13):9873-9886
pubmed: 22275372
RSC Adv. 2018 Jul 2;8(42):23937-23946
pubmed: 35540251
J Pharmacol Exp Ther. 2018 Aug;366(2):332-340
pubmed: 29891588
Diabetes. 2008 Feb;57(2):332-9
pubmed: 18024853
Int J Mol Sci. 2021 Apr 22;22(9):
pubmed: 33922165
Mol Carcinog. 2013 Oct;52(10):824-34
pubmed: 22593043
Physiol Rev. 2018 Jul 1;98(3):1169-1203
pubmed: 29717933
Molecules. 2019 Apr 08;24(7):
pubmed: 30965670
Mol Oncol. 2018 Sep;12(9):1498-1512
pubmed: 29738634
J Cancer Prev. 2014 Jun;19(2):111-7
pubmed: 25337579
Drug Metab Rev. 2016 Nov;48(4):541-567
pubmed: 27320238
PLoS One. 2014 Mar 24;9(3):e91094
pubmed: 24663328
Cancer Cell. 2018 Jul 9;34(1):21-43
pubmed: 29731393
Eur J Pharmacol. 2020 May 15;875:173031
pubmed: 32109457
Mol Cell Biol. 2009 Jan;29(2):493-502
pubmed: 19001094
Toxicol Rep. 2014;1:309-318
pubmed: 25530945
Biochim Biophys Acta. 2010 Feb;1804(2):263-74
pubmed: 19914406
Front Cell Dev Biol. 2021 Oct 08;9:729136
pubmed: 34692684
Evid Based Complement Alternat Med. 2012;2012:485042
pubmed: 22988474
Carcinogenesis. 2008 Jun;29(6):1235-43
pubmed: 18413364
Proteomics. 2001 Sep;1(9):1105-10
pubmed: 11990504
Biochem Pharmacol. 2021 Dec;194:114838
pubmed: 34774845
Front Cell Neurosci. 2022 Jan 21;15:787258
pubmed: 35126058
Carcinogenesis. 2009 Sep;30(9):1571-80
pubmed: 19608619
Front Pharmacol. 2021 Mar 30;12:578796
pubmed: 33867974
Respir Investig. 2020 Jan;58(1):28-35
pubmed: 31704266
Genes Dev. 2013 Oct 15;27(20):2179-91
pubmed: 24142871
Sci Rep. 2014 Jan 23;4:3793
pubmed: 24452734
Cell Death Dis. 2016 Apr 14;7:e2194
pubmed: 27077810
Biochem Biophys Res Commun. 1997 Jul 18;236(2):313-22
pubmed: 9240432
Oxid Med Cell Longev. 2018 Apr 18;2018:2360427
pubmed: 29849873
Curr Pharm Des. 2019;25(15):1729-1739
pubmed: 31267856
Cell Commun Signal. 2022 Jun 30;20(1):100
pubmed: 35773670
Toxins (Basel). 2019 Nov 11;11(11):
pubmed: 31717922
Toxicol Appl Pharmacol. 2019 Feb 1;364:12-21
pubmed: 30529626
Rev Endocr Metab Disord. 2015 Mar;16(1):35-45
pubmed: 25540093
Biomedicines. 2022 Aug 21;10(8):
pubmed: 36009590
Toxins (Basel). 2020 Nov 12;12(11):
pubmed: 33198257
Mol Carcinog. 2017 May;56(5):1493-1500
pubmed: 28019675
Chem Biol Interact. 2018 Jan 25;280:70-76
pubmed: 29223570
Oncogene. 2013 Oct;32(40):4825-35
pubmed: 23108405
Biomedicines. 2022 Oct 21;10(10):
pubmed: 36289931
J Med Chem. 2015 Jul 9;58(13):5242-55
pubmed: 26079183
Antioxid Redox Signal. 2014 Dec 20;21(18):2498-514
pubmed: 24892215
Expert Opin Ther Targets. 2017 Aug;21(8):781-793
pubmed: 28675319
Biology (Basel). 2020 Sep 21;9(9):
pubmed: 32967203
Free Radic Res. 2018 Dec;52(11-12):1416-1423
pubmed: 29902094
Antioxidants (Basel). 2020 Feb 25;9(3):
pubmed: 32106613
Cell Death Differ. 2014 Jun;21(6):998-1012
pubmed: 24583638
Nature. 2011 Jul 06;475(7354):106-9
pubmed: 21734707
Asian Pac J Cancer Prev. 2014;15(6):2911-6
pubmed: 24761924
Molecules. 2020 Nov 23;25(22):
pubmed: 33238435
Nucleic Acids Res. 2010 Sep;38(17):5718-34
pubmed: 20460467
Antioxidants (Basel). 2022 Mar 11;11(3):
pubmed: 35326187
Cell Metab. 2011 Apr 6;13(4):361-366
pubmed: 21459321
Cancer Prev Res (Phila). 2020 Jan;13(1):117-126
pubmed: 31619442
Drug Des Devel Ther. 2018 Sep 25;12:3181-3197
pubmed: 30288023
Biomol Ther (Seoul). 2016 Sep 1;24(5):482-8
pubmed: 27582554
Oxid Med Cell Longev. 2019 Apr 11;2019:8592348
pubmed: 31097977
Front Physiol. 2022 Sep 23;13:989793
pubmed: 36213236
Antioxid Redox Signal. 2018 Dec 10;29(17):1727-1745
pubmed: 28899199
Free Radic Biol Med. 2016 Oct;99:544-556
pubmed: 27634172
Molecules. 2021 Oct 26;26(21):
pubmed: 34770867
Tumour Biol. 2017 Jun;39(6):1010428317705510
pubmed: 28621229
Molecules. 2023 Apr 14;28(8):
pubmed: 37110693
Cancers (Basel). 2018 Sep 03;10(9):
pubmed: 30177619
Oncotarget. 2016 Nov 8;7(45):73593-73606
pubmed: 27713154
Oncotarget. 2018 Jun 5;9(43):27104-27116
pubmed: 29930754
FASEB J. 2013 Feb;27(2):414-23
pubmed: 23109674
Sci Rep. 2017 Feb 02;7:39950
pubmed: 28150717
Carcinogenesis. 2007 Nov;28(11):2398-403
pubmed: 17602169
J Recept Signal Transduct Res. 2022 Feb;42(1):88-94
pubmed: 33256538
Molecules. 2021 Mar 05;26(5):
pubmed: 33808001
Genes Cells. 2011 Feb;16(2):123-40
pubmed: 21251164
Am J Med. 2015 May;128(5):461-70
pubmed: 25554368
Iran J Basic Med Sci. 2017 May;20(5):516-529
pubmed: 28656087
Oxid Med Cell Longev. 2019 Jul 14;2019:9372182
pubmed: 31396308
Molecules. 2021 Jun 03;26(11):
pubmed: 34204857
Cancer Biol Ther. 2016 Sep;17(9):925-34
pubmed: 27416292
J Ethnopharmacol. 2009 Oct 29;126(1):5-17
pubmed: 19686830
J Cell Physiol. 2020 Apr;235(4):3119-3130
pubmed: 31549397
Oxid Med Cell Longev. 2017;2017:9237263
pubmed: 29104732
Chem Biol Interact. 2013 Oct 25;206(1):100-8
pubmed: 23994249
Antioxidants (Basel). 2021 Dec 30;11(1):
pubmed: 35052602
BMC Cancer. 2015 Mar 13;15:118
pubmed: 25851054
Phytomedicine. 2016 Nov 15;23(12):1494-1503
pubmed: 27765370
Acta Pharm Sin B. 2015 Jul;5(4):285-99
pubmed: 26579458
Cell Death Dis. 2018 Jan 11;9(1):15
pubmed: 29323103
Biomed Res Int. 2020 Sep 29;2020:1269624
pubmed: 33062666
Curr Med Chem. 2012;19(21):3523-31
pubmed: 22680628
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992
pubmed: 27646922
Phytochemistry. 2021 Oct;190:112880
pubmed: 34311277
Redox Biol. 2015 Dec;6:51-72
pubmed: 26184557
Cells. 2022 Aug 04;11(15):
pubmed: 35954245
Cancer Med. 2019 May;8(5):2252-2267
pubmed: 30929309
Antioxidants (Basel). 2021 Mar 25;10(4):
pubmed: 33805928
Free Radic Biol Med. 2009 Nov 1;47(9):1304-9
pubmed: 19666107
Cancer Manag Res. 2020 Jan 30;12:695-702
pubmed: 32099466
Antioxidants (Basel). 2020 Dec 04;9(12):
pubmed: 33291560
Biomedicines. 2021 Aug 30;9(9):
pubmed: 34572304
Mol Biol Rep. 2020 Aug;47(8):5817-5829
pubmed: 32661875
Toxicol In Vitro. 2021 Feb;70:105038
pubmed: 33148531
Cancer Cell. 2012 Jul 10;22(1):66-79
pubmed: 22789539
Oxid Med Cell Longev. 2020 Jul 19;2020:9867595
pubmed: 32765809
Antioxid Redox Signal. 2007 Jan;9(1):49-89
pubmed: 17115887
Free Radic Biol Med. 2022 Nov 1;192:246-260
pubmed: 36181972
Nat Cell Biol. 2008 Feb;10(2):138-48
pubmed: 18204439
Ann Epidemiol. 1994 Jan;4(1):1-10
pubmed: 8205268
JAMA. 2011 Oct 12;306(14):1549-56
pubmed: 21990298
J Med Food. 2016 Jun;19(6):578-85
pubmed: 27119744
Cells. 2021 Jul 24;10(8):
pubmed: 34440648
Cancer Res. 2013 Jul 15;73(14):4406-17
pubmed: 23674500
Eur J Pharmacol. 2019 Dec 1;864:172717
pubmed: 31586637
Int J Mol Sci. 2019 Apr 24;20(8):
pubmed: 31022969
Bioorg Med Chem Lett. 2018 Sep 15;28(17):2816-2826
pubmed: 30122223
Biomolecules. 2020 May 20;10(5):
pubmed: 32443774
Acta Biochim Biophys Sin (Shanghai). 2017 Aug 1;49(8):696-705
pubmed: 28810706
Chin Med. 2011 Jul 22;6(1):27
pubmed: 21777476
Free Radic Biol Med. 2019 Apr;134:429-444
pubmed: 30703480
Biomed Pharmacother. 2018 Aug;104:458-464
pubmed: 29793178
Inflammation. 2018 Oct;41(5):1640-1647
pubmed: 29748730
Food Chem Toxicol. 2010 Apr;48(4):1105-10
pubmed: 20138204
Int J Mol Sci. 2022 Dec 07;23(24):
pubmed: 36555089
Free Radic Biol Med. 2011 Jun 1;50(11):1599-609
pubmed: 21402146
Free Radic Res. 2014 May;48(5):607-21
pubmed: 24666416
Clin Cancer Res. 2010 Jul 15;16(14):3743-53
pubmed: 20534738
Oxid Med Cell Longev. 2016;2016:2746457
pubmed: 27340506
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19589-94
pubmed: 18048326
Antioxidants (Basel). 2017 Jul 10;6(3):
pubmed: 28698499
Nat Rev Cancer. 2012 Jul 19;12(8):564-71
pubmed: 22810811
Cancer Sci. 2007 Jan;98(1):19-24
pubmed: 17083568
Biochem Biophys Res Commun. 2014 May 16;447(4):602-8
pubmed: 24747074
Molecules. 2021 Mar 25;26(7):
pubmed: 33805996

Auteurs

Darinka Gjorgieva Ackova (D)

Department of Applied Pharmacy, Division of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip, Krste Misirkov Str., No. 10-A, P.O. Box 201, 2000 Stip, North Macedonia.

Viktorija Maksimova (V)

Department of Applied Pharmacy, Division of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip, Krste Misirkov Str., No. 10-A, P.O. Box 201, 2000 Stip, North Macedonia.

Katarina Smilkov (K)

Department of Applied Pharmacy, Division of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip, Krste Misirkov Str., No. 10-A, P.O. Box 201, 2000 Stip, North Macedonia.

Brigitta Buttari (B)

Department of Cardiovascular and Endocrine-Metabolic Diseases and Aging, Italian National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.

Marzia Arese (M)

Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza University of Rome, Piazz. le A. Moro 5, 00185 Rome, Italy.

Luciano Saso (L)

Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.

Classifications MeSH